Molecular pharmacology of the interaction of anthracyclines with iron

Molecular Pharmacology

Volumn 68, Issue 2, 2005, Pages 261-271

  Xu, X ^a   Persson, H L ^b   Richardson, D R ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; ANTHRACYCLINE; CERULOPLASMIN; DAUNORUBICIN; DEFERASIROX; DEFEROXAMINE; DOXORUBICIN; EPIRUBICIN; FERROPORTIN 1; FREE RADICAL; HEPCIDIN; HEPHASTIN; HYDRAZONE DERIVATIVE; IRON; IRON CHELATE; IRON COMPLEX; IRON REGULATORY FACTOR; MESSENGER RNA; PYRIDOXAL ISONICOTINOYL HYDRAZONE; RAZOXANE; SALICYLALDEHYDE ISONICOTINOYL HYDRAZONE; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRIPAMIDE; UNCLASSIFIED DRUG;

BREAST CANCER; CARDIOTOXICITY; DRUG INDUCED DISEASE; HEART PROTECTION; HOMEOSTASIS; HUMAN; IRON CHELATION; IRON HOMEOSTASIS; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; LYSOSOME MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROTEIN RNA BINDING; REGULATORY MECHANISM; SHORT SURVEY;

ANIMALS; ANTHRACYCLINES; DRUG INTERACTIONS; HUMANS; IRON;

EID: 23044447053     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.105.013383     Document Type: Short Survey

References (61)

1. Aouad F, Florence A, Zhang Y, Collins F, Henry C, Ward RJ, and Crichton RR (2002) Evaluation of new iron chelators and their therapeutic potential. Inorg Chim Acta 339:470-480.
2. Brazzolotto X, Andriollo M, Guiraud P, Favier A, and Moulis JM (2003) Interactions between doxorubicin and the human iron regulatory system. Biochim Biophys Acta 1593:209-218.
3. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, Majorano N, Totaro A, and Gasparini P (2000) The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 25:14-15.
4. Cheng Y, Zak O, Aisen P, Harrison SC, and Walz T (2004) Structure of the human transferrin receptor-transferrin complex. Cell 116:565-576.
5. Corna G, Santambrogio P, Minotti G, and Cairo G (2004) Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem 279:13738-13745.
6. Curran CF, Narang PK, and Reynolds RD (1991) Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity. Cancer Treat Rev 18:241-252.
7. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, et al. (2000) Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature (Lond) 403:776-781.
8. Esposito BP, Epsztejn S, Breuer W, and Cabantchik ZI (2002) A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal Biochem 304:1-18.
9. Ganz T (2003) Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102:783-788.
10. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
11. Gianni L and Myers C (1992) The role of free radical formation in the cardiotoxicity of anthracyclines, in Cancer Treatment and the Heart (Muggia FM, Green MD, and Speyer JL eds) pp 9-46, Johns Hopkins University Press, Baltimore.
12. Guo B, Brown FM, Phillips JD, Yu Y, and Leibold EA (1995) Characterization and expression of iron regulatory protein 2 (IRP2). Presence of multiple IRP2 transcripts regulated by intracellular iron levels. J Biol Chem 270:16529-16535.
13. Harrison PM and Arosio P (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275:161-203.
14. Hasinoff BB (1998) Chemistry of dexrazoxane and analogues. Semin Oncol 25 (4 Suppl 10):3-9.
15. Hasinoff BB, Patel D, and Wu X (2003) The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med 35:1469-1479.
16. Hentze MW and Kuhn LC (1996) Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide and oxidative stress. Proc Natl Acad Sci USA 93:8175-8182.
17. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, and Link G (2001) ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 97:1115-1122.
18. Hurwitz SJ, Terashima M, Mizunuma N, and Slapak CA (1997) Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes. Blood 89:3745-3754.
19. Jung K and Reszka R (2001) Mitochondria as subcellular targets for clinically useful anthracyclines. Advanced Drug Delivery Rev 49:87-105.
20. Kawabata H, Germain RS, Ikezoe T, Tong X, Green EM, Gombart AF, and Koeffler HP (2001) Regulation of expression of murine transferrin receptor 2. Blood 98:1949-1954.
21. Kawabata H, Yang R, Hirama T, Vuong PT, Kawano S, Gombart AF, and Koeffler HP (1999) Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 274:20826-20832.
22. Keizer HG, Pinedo HM, Schuurhuis GJ, and Joenje H (1990) Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47:219-231.
23. Kim HY, Klausner RD, and Rouault TA (1995) Translational repressor activity is equivalent and is quantitatively predicted by in vitro RNA binding for two ironresponsive element-binding proteins, IRP1 and IRP2. J Biol Chem 270:4983-4986.
24. Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, and Kalyanaraman B (2002) Transferrin receptor-dependent iron uptake is responsible for doxorubicinmediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem 277:17179-17187.
25. Kwok JC and Richardson DR (2002) Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Mol Pharmacol 62:888-900.
26. Kwok JC and Richardson DR (2003) Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 63:849-861.
27. Kwok JC and Richardson DR (2004) Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors and lysosomotropic agents. Mol Pharmacol 65:181-195.
28. LaVaute T, Smith S, Cooperman S, Iwai K, Land W, Meyron-Holtz E, Drake SK, Miller G, Abu-Asab M, Tsokos M, et al. (2001) Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 27:209-214.
29. Lebron JA, West AP Jr, and Bjorkman PJ (1999) The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor. J Mol Biol 294:239-245.
30. Link G, Ponka P, Konijn AM, Breuer W, Cabantchik ZI, and Hershko C (2003) Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood 101:4172-4179.
31. Meyron-Holtz EG, Ghosh MC, Iwai K, LaVaute T, Brazzolotto X, Berger UV, Land W, Ollivierre-Wilson H, Grinberg A, Love P, et al. (2004) Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis. EMBO (Eur Mol Biol Organ) J 23:386-395.
32. Minotti G, Cavaliere AF, Mordente A, Rossi M, Schiavello R, Zamparelli R, and Possati G (1995) Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Investig 95:1595-1605.
33. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
34. Minotti G, Recalcati S, Mordente A, Liberi G, Calafiore AM, Mancuso C, Preziosi P, and Cairo G (1998) The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J 12:541-552.
35. Minotti G, Ronchi R, Salvatorelli E, Menna P, and Cairo G (2001) Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61:8422-8428.
36. Miranda CJ, Makui H, Soares RJ, Bilodeau M, Mui J, Vali H, Bertrand R, Andrews NC, and Santos MM (2003) HFE deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 102:2574-2580.
37. Myers C (1998) The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 25:10-14.
38. Napier I, Ponka P, and Richardson DR (2005) Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood 105:1867-1874.
39. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, and Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (Wash DC) 306:2090-2093.
40. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, et al. (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, doubleblind, placebo-controlled, dose-escalation trial. Lancet 361:1597-1602.
41. Persson HL, Nilsson KJ, and Brunk UT (2001) Novel cellular defenses against iron and oxidation: ferritin and autophagocytosis preserve lysosomal stability in airway epithelium. Redox Rep 6:57-63.
42. Petrak JV and Vyoral D (2001) Detection of iron-containing proteins contributing to the cellular labile iron pool by a native electrophoresis metal blotting technique. J Inorg Biochem 86:669-675.
43. Petrat F, de Groot H, and Rauen U (2001) Subcellular distribution of chelatable iron: a laser scanning microscopic study in isolated hepatocytes and liver endothelial cells. Biochem J 356:61-69.
44. Philpott CC, Haile D, Rouault TA, and Klausner RD (1993) Modification of a free Fe-S cluster cysteine residue in the active iron-responsive element-binding protein prevents RNA binding. J Biol Chem 268:17655-17658.
45. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, and Loreal O (2001) A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276:7811-7819.
46. Radisky DC and Kaplan J (1998) Iron in cytosolic ferritin can be recycled through lysosomal degradation in human fibroblasts. Biochem J 336:201-205.
47. Richardson DR and Ponka P (1997) The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1331:1-40.
48. Richardson DR and Ponka P (1998) Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 131:306-315.
49. Saad SY, Najjar TA, and Al-Rikabi AC (2001) The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res 43:211-218.
50. Schroterova L, Kaiserova H, Baliharova V, Velik J, Gersl V, and Kvasnickova E (2004) The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res 53:683-691.
51. Simunek T, Klimtova I, Kaplanova J, Sterba M, Mazurova Y, Adamcova M, Hrdina R, Gersl V, and Ponka P (2005) Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol Res 51:223-231.
52. Singal PK, Iliskovic N, Li T, and Kumar D (1997) Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 11:931-936.
53. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, and Gams RA (1997a) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15:1333-1340.
54. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, et al. (1997b) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332.
55. Thomas CE and Aust SD (1986) Reductive release of iron from ferritin by cation free radicals of paraquat and other bipyridyls. J Biol Chem 261:13064-13070.
56. Voest EE, van Acker SA, van der Vijgh WJ, van Asbeck BS, and Bast A (1994) Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 26:1179-1185.
57. Vogt TM, Blackwell AD, Giannetti AM, Bjorkman PJ, and Enns CA (2003) Heterotypic interactions between transferrin receptor and transferrin receptor 2. Blood 101:2008-2014.
58. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, Gitschier J, and Anderson GJ (1999) Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 21:195-199.
59. West AP Jr, Bennett MJ, Sellers VM, Andrews NC, Enns CA, and Bjorkman PJ (2000) Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE. J Biol Chem 275:38135-38138.
60. Wu X and Hasinoff BB (2005) The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anticancer Drugs 16:93-99.
61. Zhang AS, Sheftel AD, and Ponka P (2005) Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood 105:368-375.